New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis
Journal
BMJ Mental Health
ISSN
2755-9734
Type
journal article
Date Issued
2023
Author(s)
Andrea Cipriani
;
Soraya Seedat
;
Lea Milligan
;
Georgia Salanti
;
Malcolm Macleod
;
;
James Thomas
;
Susan Michie
;
Toshi A Furukawa
;
David Gilbert
;
Karla Soares-Weiser
;
Carmen Moreno
;
Stefan Leucht
;
Matthias Egger
;
Parisa Mansoori
;
James M Barker
;
Spyridon Siafis
;
Edoardo Giuseppe Ostinelli
;
Robert McCutcheon
;
Simonne Wright
;
Matilda Simpson
;
Olufisayo Elugbadebo
;
Virginia Chiocchia
;
Thomy Tonia
;
Rania Elgarf
;
Ayse Kurtulmus
;
Emily Sena
;
Ouma Simple
;
Niall Boyce
;
Sophie Chung
;
Anjuli Sharma
;
Miranda Wolpert
;
Jennifer Potts
;
Julian H Elliott
Abstract
In anxiety, depression and psychosis, there has been frustratingly slow progress in developing novel therapies that make a substantial difference in practice, as well as in predicting which treatments will work for whom and in what contexts. To intervene early in the process and deliver optimal care to patients, we need to understand the underlying mechanisms of mental health conditions, develop safe and effective interventions that target these mechanisms, and improve our capabilities in timely diagnosis and reliable prediction of symptom trajectories. Better synthesis of existing evidence is one way to reduce waste and improve efficiency in research towards these ends. Living systematic reviews produce rigorous, up-to-date and informative evidence summaries that are particularly important where research is emerging rapidly, current evidence is uncertain and new findings might change policy or practice. Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis (GALENOS) aims to tackle the challenges of mental health science research by cataloguing and evaluating the full spectrum of relevant scientific research including both human and preclinical studies. GALENOS will also allow the mental health community—including patients, carers, clinicians, researchers and funders—to better identify the research questions that most urgently need to be answered. By creating open-access datasets and outputs in a state-of-the-art online resource, GALENOS will help identify promising signals early in the research process. This will accelerate translation from discovery science into effective new interventions for anxiety, depression and psychosis, ready to be translated in clinical practice across the world.
Volume
26
Number
1